Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced by Celldex Therapeutics.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced by Celldex Therapeutics
- Full results, including financial metrics and management commentary, contained in Exhibit 99.1
- Investor focus: cash position, operating expenses, and clinical-development funding capacity
Item EX-99.1 · Exhibit EX-99.1
- Cash and marketable securities $717.6M after $323.8M offering proceeds, funding planned operations through 2028
- Phase 3 CSU enrollment complete with 1,939 patients, topline data expected September/October 2026
- Planned barzolvolimab BLA submission in 2027 creates a potential transition toward commercialization
- Second-quarter R&D expense $67.5M, up from $54.2M, reflecting expanded barzolvolimab trials and manufacturing
- PN Phase 2 failed primary and key secondary endpoints, prompting discontinuation and narrowing barzolvolimab’s opportunity set
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.